Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4581-4590 Newer>

The Motley Fool February 13, 2008 Brian Orelli	Schering-Plough Has No Love for the Media Apart from the press bashing regarding the company's cholesterol-lowering drug Enhance, Schering reported a pretty nice quarter.
The Motley Fool February 13, 2008 Stephen Albainy-Jenei	One Privileged Position Biomedical Patent Management sued the California Department of Health Services, claiming patent infringement, but the State of California can claim immunity from patent suits.
The Motley Fool February 12, 2008 Brian Lawler	A Pre-Emptive Strike on the FDA Adolor will likely be waiting an extra three months for a decision on its lead drug Entereg.
The Motley Fool February 11, 2008 Brian Lawler	No Fire Fueling Flamel's Top Drug Flamel Technologies had a rough 2007; and with only one drug determining its near-term success, investors should be cautious of this drugmaker.
The Motley Fool February 8, 2008 Brian Lawler	Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses.
The Motley Fool February 8, 2008 Brian Orelli	Merck in Lukewarm Water The pharmaceutical's settlement ends a government probe into Medicaid overcharging allegations.
The Motley Fool February 8, 2008 Brian Lawler	Hold on to GlaxoSmithKline This might be a tough year for the big pharma company, but its pipeline makes it a keeper.
Chemistry World February 7, 2008 Hepeng Jia	Profile: Vaccine Trailblazer Yin Weidong is one of the leading lights of China's fast growing biotech industry and Sinovac the first Chinese biotech firm listed on the US stock exchange.
The Motley Fool February 7, 2008 Brian Orelli	Invitrogen Integrates After a rough 2006 in which it struggled to integrate its acquisitions, Invitrogen used 2007 to show why it made all of its purchases.
The Motley Fool February 7, 2008 Brian Orelli	A Lab Match Made in Heaven The case of Thermo Electron and Fisher Scientific shows why mergers work.
<Older 4581-4590 Newer> Return to current articles.